It has been previously found that local administration of Balb/c plasmacytoma cells transformed and made non-tumorigenic by insertion of the cloned murine interleukin-2 (IL-2) gene induced regressions of a variety of murine tumours including the original Balb/c plasmacytoma X63-Ag8.653 growing in syngeneic mice. The tumour-inhibitory effect of the plasmacytoma cells transformed by IL-2 cDNA and designated as X63-m-IL-2 was due to their high constitutive production of IL-2. Here we show that admixture of syngeneic spleen cells to the X63-m-IL-2 transformants substantially (P < 0.025) increased the antitumour efficacy of the transformants. Balb/c spleen cells co-cultivated with X63-m-IL-2 cells in vitro yielded predominantly Thy 1.2+, CD3+, LFA-1+ lymphocytes, cytolytic for the X63-Ag8.653 plasmacytoma as well as for other murine tumours, including the X63-m-IL-2 target cells.

Institute of Molecular Genetics Czechoslovak Academy of Sciences Prague

Zobrazit více v PubMed

Blankenstein T, Qin Z, Überla K, Müller T, Rosen H, Volk H-D, Diamantstein T (1991) Tumor suppression after tumor cell-target tumor necrosis factor alpha gene transfer. J Exp Med 173:1047–1052 PubMed PMC

Bubeník J (1990) Local and regional immunotherapy of cancer with interleukin 2 (guest editorial). J Cancer Res Clin Oncol 116:1–7 PubMed PMC

Bubeník J, Indrová M (1987) The anti-tumour efficacy of human recombinant interleukin-2: correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin-2 immunotherapy in vivo. Cancer Immunol Immunother 24:269–271 PubMed PMC

Bubeník J, Šímová J, Jandlová T (1989/1990) Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol Lett 23:287–292 PubMed

Bubeník J, Lotzová E, Zeuthen J, Bubeníková D, Šímová J, Indrová M (1991) Gene therapy of cancer: use of interleukin-2 (IL-2) gene transfer in local immunotherapy. J Exp Clin Cancer Res 10:213–220

Bubeník J, Zeuthen J, Šímová J, Jandlová T, Bubeníková D, Radzikowski C (1992) Activation and phenotyping of LAK generated by exposure to product of cells transformed by interleukin 2 cDNA. Anticancer Res 12:965–968 PubMed

Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397–403 PubMed

Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E (1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217–1224 PubMed PMC

Goldie H, Butler Ch, Anderson MM (1953) Growth characteristics of free C1498 (granulocytic leukemia) tumor cells in the peritoneal fluid and the blood of C57 mice. Cancer Res 13:125–129 PubMed

Karasuyama H, Melchers F (1988) Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2,3,4 or 5, using modified cDNA expression vectors. Eur J Immunol 18:97–104 PubMed

Kearney JF, Radbruch A, Liesegang B, Rajewsky K (1979) A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 123:1548–1550 PubMed

Kedar E, Herberman RB (1982) Induction of NK-like anti-tumor reactivity in vitro and in vivo by IL-2. In: Herberman RB (ed) NK cells and other natural effector cells. Academic Press. New York, pp 859–861

Mulé JJ, Yang J, Shu S, Rosenberg SA (1986) The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. J Immunol 136:3899–3903 PubMed

Rosenberg S, Lotze MT (1986) Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol 4:681–713 PubMed

Tepper RI, Pattengale PK, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503–512 PubMed

Wigzell H, Ramstedt U (1986) Natural killer cells. In: Weyr MM (ed) Cellular immunology, vol 2. Blackwell Scientific, Oxford, pp 601–609